SAB BIO Announces Founding of Clinical Advisory Board to Guide the Development of SAB-142 for Type 1 Diabetes

Core Viewpoint - SAB Biotherapeutics, Inc. has established a clinical advisory board to guide the development of its leading therapeutic candidate, SAB-142, aimed at delaying the onset or progression of type 1 diabetes (T1D) [1][2][3] Company Overview - SAB Biotherapeutics is a clinical-stage biopharmaceutical company focused on developing human immunoglobulins to treat immune and autoimmune disorders, with a particular emphasis on T1D [8][9] - The company's lead asset, SAB-142, is designed to modify the disease course of T1D by delaying its onset and potentially preventing progression [8] Clinical Advisory Board - The newly formed clinical advisory board consists of leading experts in T1D therapy development, expected to provide strategic direction and insights on clinical protocols [2][4] - Founding members include prominent figures from various prestigious institutions, enhancing the company's research and development capabilities [4] SAB-142 Overview - SAB-142 is a human alternative to rabbit anti-thymocyte globulin (ATG), with a mechanism of action similar to rabbit ATG, which has shown efficacy in slowing disease progression in clinical trials [5][6] - Unlike rabbit ATG, SAB-142 is a human antibody, allowing for safe and consistent re-dosing without the adverse immune reactions associated with animal-derived treatments [7] Mechanism of Action - SAB-142 targets multiple immune cells that destroy pancreatic beta cells, aiming to preserve insulin-producing cells and regulate blood sugar levels [6][7]